• Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
  Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, Jeffrey R. Infante, Alain Mita, Antoine Italiano, Emiliano Calvo, Victor Moreno, Barbara Adamo, Anas Gazzah, Bob Zhong, Suso J. Platero, Johan W. Smit, Kim Stuyckens, Moitreyee Chatterjee-Kishore, Jordi Rodon, Vijay Peddareddigari, Feng R. Luo and Jean-Charles Soria. J Clin Oncol. 2015 Aug 31. pii: JCO.2014.60.7341

• A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
  Sereno M, Moreno V, Moreno Rubio J, Gómez-Raposo C, García Sánchez S, Hernández Jusdado R, Falagan S, Zambrana Tébar F, Casado Sáenz E. Anticancer Drugs. 2015 Oct;26(9):1004-7

• A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
  Joaquin Mateo, David Olmos, Herlinde Dumez, Srinivasu Poondru, Nancy L Samberg, Sharon Barr, Jan M Van Tornout, Fei Jie, Shahneen Sandhu, Daniel S Tan, Victor Moreno, Patricia M LoRusso, Stan B Kaye and Patrick Schöffski. Br J Cancer. 2016 Mar 22. doi: 10.1038/bjc.2016.59

• GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
  Pérez-Segura , Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. Clin Transl Oncol. 2015 Nov 5.

• Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.
  González-Alonso P, Chamizo C, Moreno V, Madoz-Gúrpide J, Carvajal N, Daoud L, Zazo S, Martín-Aparicio E, Cristóbal I, Rincón R, García-Foncillas J, Rojo F Int J Mol Sci. 2015 Aug 17;16(8):19447-57

• MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer
  Caramés C, Cristóbal I, Moreno V, del Puerto L, Moreno I, Rodriguez M, Marín JP, Correa AV, Hernández R, Zenzola V, Hernández T, León A, Martín JI, Sánchez-Fayos P, García-Olmo D, Rojo F, Goel A, Fernandez-Aceñero MJ, García-Foncillas J. Int J Colorectal Dis. 2015 Jul;30(7):899-906

• Antitumor activity in RAS-driven tumors by blocking AKT and MEK
  Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Clin Cancer Res. 2015 Feb 15;21(4):739-48.

• First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
  Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS Clin Cancer Res. 2015 Jan 1;21(1):77-86.

• Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study.
  Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Clin Cancer Res. 2014 Nov 15;20(22):5663-71

• Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
  Moreno V, García-Carbonero R, Maurel J, Feliu J Cancer. 2013 Nov 14. doi: 10.1002/cncr.28449.

• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
  Barber LJ1, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. J Pathol. 2013 Feb;229(3):422-9

• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
  Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter, Robert Iannone, Stan B Kaye, Johann S de Bono, Robert M Wenham Lancet Oncol. 2013 Aug;14(9):882-92

• Thymoma and thymic carcinoma in the target therapies era.
  Lamarca A, Moreno V, Feliu J. Cancer Treat Rev. 2013 Aug;39(5):413-20. doi: 10.1016/j.ctrv.2012.11.005. Epub 2012 Dec 20. Review

• Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives.
  Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J. Cancer Treat Rev. 2013 Mar 16. doi:pii: S0305-7372(13)00035-2. 10.1016/j.ctrv.2013.02.004.

• Association of Creatine Kinase and Skin Toxicity in Phase I Trials of Anticancer Agents
  V Moreno Garcia, P Thavasu, M Blanco Codesido, LR Molife, JV Pedersen, M Puglisi, B Basu, K Shah, J Iqbal, JS de Bono, SB Kaye, U Banerji British Journal of Cancer 2012 Nov 20;107 (11):1797-800. doi: 10.1038/bjc.2012.482. Epub 2012 Oct 25

• Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
  Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono JS, Kaye SB, Molife LR, Banerji U Oncology. 2012;83(4):177-82. Epub 2012 Aug 7

• The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
  Vitfell-Pedersen J, Yap TA, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB. Eur J Gynaecol Oncol. 2012;33(2):211-3.

• The role of capecitabine in locally advanced rectal cancer treatment: an update.
  Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, Feliu J. Drugs. 2012, May 28; 72 (8): 1057-73

• Combining Antiangiogenics to Overcome Resistance: rationale and clinical experience.
  Moreno Garcia V, Basu B, Molife LR, Kaye SB. Clinical Cancer Research. 2012 Apr 30. [Epub ahead of print]

• Upregulation of Trefoil Factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
  Casado E*, Garcia VM*, Sánchez JJ, Gómez del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno-Rubio J, López R, García-Cabezas MA, Burgos E, de Castro J, Belda C, López-Gómez M, Gómez-Raposo C, Zambrano F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, Cejas P. International Journal of Radiation Oncology*Biology*Physics. 2012. Apr 18

• ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications.
  Sereno M, Cejas P, Moreno V, Belda-Iniesta C, López R, Nistal M, Feliu J, De Castro Carpeño J. Int J Oncol. 2012 Feb 16. doi: 10.3892/ijo.2012.1378

• Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials
  Blanco Codesido M, Tesainer Brunetto A, Frentzas S, Moreno Garcia V, Papadatos-Pastos D, Pedersen JV, Trani L, Puglisi M, Molife LR, Banerji U. Oncology. 2011;81(2):135-40. Epub 2011 Oct 6.

• Parallel Anticancer Drug Development and Molecular Stratification to Qualify Predictive Biomarkers: Dealing with Obstacles Hindering Progress
  Victor Moreno Garcia, Philippe A Cassier, Johann De Bono. Cancer Discovery. August 2011 1:207-212

• A combined strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer
  Enrique Casado , Victor Moreno Garcia, Jose Javier Sánchez, Montserrat Blanco, Joan Maurel, Jaime Feliu, Carlos Fernández-Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda, María Sereno, Benito Sánchez-Llamas, Emilio Burgos, Miguel Ángel García-Cabezas, Noemí Manceñido, Rosa Miquel, Damián García-Olmo, Manuel González-Barón, Paloma Cejas. Clin Cancer Res. 2011 Jun 15;17(12):4145-54

• Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy.
  Cejas P, López-Gómez M, Aguayo C, Madero R, Moreno-Rubio J, Carpeño JD, Belda-Iniesta C, Barriuso J, García VM, Díaz E, Burgos E, Gonzalez-Barón M, Feliu J. Current Cancer Drug Targets. 2011 Jan 10.

• Immunohistochemical analysis of tumour regression grade for rectal tumors after neoadjuvant chemoradiotherapy.
  Víctor Moreno García; Enrique Casado; Jaime Feliu Batlle; Emilio Burgos; Javier de Castro; Cristóbal Beld; Jorge Barriuso; Jose Javier Sánchez; Miguel Ángel García-Cabezas; Manuel González-Barón; Paloma Ceja). Colorectal Disease. 2011 Sep;13(9):989-98.

• KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis
  Paloma Cejas, Miriam López-Gómez, Cristina Aguayo, Rosario Madero, Javier de Castro Carpeño, Cristóbal Belda-Iniesta, Jorge Barriuso, Víctor Moreno García, Javier Larrauri, Rocío López, Enrique Casado, Manuel Gonzalez-Barón, Jaime Feliu PLOS One. 2009 Dec 18; 4(12):e8199.

• Prognostic Value of Carcinoembryonic Antigen Level in Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy
  Moreno García V, Cejas P, Blanco M, Feliu J, Castro J, Belda C, Barriuso J, Sanchez JJ, Gonzalez Baron M. International Journal of Colorectal Diseases. 2009 Jul;24(7):741-8

• Primary cardiac osteosarcoma.
  López M, Pinto A, Moreno V, Díaz M, Gonzalez Barón M Clin Transl Oncol. 2008 Aug ,10:515-516.

• Update in oral chemotherapeutic management of cancer.
  Hernández Agudo E, Moreno García V, Feiu J, Gonzalez-Baron M. Formación Médica Continuada: Oncología. 2008 Abril. 7: 19-31. [Not Indexed]

• Meningeal relapse by follicular lymphoma as a single mass.
  Moreno García V, Redondo A, Fernández Zubillaga A, González-Barón M. Clin Transl Oncol. 2008 Mar;10(3):180-1.

• New screening method for lung cancer by detecting volatile organic compounds in breath.
  Belda-Iniesta C, de Castro Carpeño J, Carrasco JA, Moreno V, Casado Sáenz E, Feliu J, Sereno M, García Río F, Barriuso J, González Barón M. Clin Transl Oncol. 2007 Jun;9(6):364-8

• Abdominal pain and fever with two months of duration.
  Moreno Garcia V, Sancho Bueso T, Barrionuevo Ramos M, Vazquez Rodriguez JJ. Rev Clin Esp. 2007 Jan;207(1):48-50 [Article in Spanish]

• Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1,2 dimethyl-hydrazine (DMH)
  Coca S, Enrech S, Moreno Garcia V, Saez MA, Gutierrez C, Colmenarejo A, Hernandez JM, Perez Piqueras J. Rev Esp Enferm Dig. 2005 Sep;97(9):619-28

INTERNACIONALES:

• GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive high-grade glioma (HGG) in Spain
  Pedro Pérez-Segura, Ray Manneh Kopp, Isaac Ceballos, Almudena Garcia, Manuel Benavides, Jose Fuster, M. Angeles Vaz, Juana Maria Cano, Jose Pablo Berros, Marta Covela, Victor Moreno, et al.
  2014. ASCO Annual meeting. Poster

• Analysis of patients with locally advanced NSCLC after induction therapy: Importance of nodal downstaging, and prognostic factors for survival.
  Jose Antonio Lopez-Vilariño, Manuel Domine, Francisco Lobo, Ana Leon, Victoria Casado, Gustavo Rubio, Jose Ignacio Martin Valades, Yann Izarzugaza, Juan Luis Arranz, Miriam Dorta, Victor Moreno, et al.
  2014. ASCO Annual meeting. ePoster.

• A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.
  Khurum Hayat Khan, Li Yan, Janusz Mezynski, Amita Patnaik, Victor Moreno, Kyriakos P. Papadopoulos, Chris R. Garrett, Michael Ong, Keith A. Shannon, Anne Morosky, Eric H. Rubin, Ernestina Tetteh, Jeffrey Skolnik, Ian C. Smith, Paul D. Smith, Johann Sebastian De Bono, Anthony W. Tolcher
  2012 ASCO Annual Meeting. Poster.

• A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors
  Gianluca Del Conte, Rastilav Bahleda, Victor Moreno, Silvia Damian, Antonella Perotti, Nathalie Lassau, Françoise Farace, Michael Ong, Sarah Jane Stimpson, Nina Tunariu, Sandrine Micallef, Brigitte Demers, Corina Oprea, Giuseppe Capri, Jean-Charles Soria, Cristiana Sessa, L Rhoda Molife
  2012 ASCO Annual meeting. Poster

• Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
  Avinash Gupta, Victor Moreno, Emma Jane Dean, Yvette Drew, Shibani Nicum, Malcolm Ranson, Ruth Plummer, Helen Swaisland, Wendy Burke, Peter McCormack, Ilian Tchakov, Mark R. Middleton, Stanley B. Kaye, L Rhoda Molife
  2012 ASCO Annual meeting. Poster

• Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study
  Ana Custodio, Juan Moreno, Jorge Aparicio, Javier Gallego Plazas, Carlos Fernandez-Martos, Ricardo Yaya, Ana M Calatrava, Juan Maurel, Emilio Burgos, Eva Tejerina, Jorge Barriuso, Victor Moreno, Virginia Martinez Marín, Javier De Castro, Angela Lamarca, Pablo Lapunzina, Rosario Madero, Paloma Cejas, Jaime Feliu
  2012 ASCO Annual meeting. Poster

• Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08.
  Jorge Barriuso, Victor Moreno, Monica Coronado, Ignacio Galicia, Irene Soria, Javier de Castro, Cristobal Belda-Iniesta, Virginia Martinez Marín, Ana Custodio, Andres Redondo, Angela Lamarca, Nadia Hindi, Jose Luis Subiza, Jesus Frias, Jaime Feliu, Antonio Carcas
  2012 ASCO Annual meeting. Poster

• Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain.
  Victor Moreno, Brezo Martinez-Amores, Jorge Barriuso, Laura Mezquita, Inmaculada Ibañez de Cáceres, Angel Ayuso Sacido, Jose Maria Peña, Rosario Perona, Cristobal Belda-Iniesta.
  2012 ASCO Annual meeting. Poster

• Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study.
  Jaime Feliu, Ana Custodio, Juan Moreno, Jorge Aparicio, Javier Gallego, Ricardo Yaya, Juan Maurel, Carlos Fernandez-Martos, Antonio Sánchez, Ana M Calatrava, Emilio Burgos, Virginia Martinez Marín, Javier De Castro, Jorge Barriuso, Victor Moreno, Nadia Hindi, Rosario Madero, Pablo Lapunzina, Paloma Cejas
  2012 ASCO Annual meeting. Poster

• Cost-effectiveness analysis per life-year gained based on predictors of response for first-line metastatic colorectal cancer therapy in Spain.
  Cristobal Belda-Iniesta, Victor Moreno, Brezo Martinez-Amores, Jorge Barriuso, Laura Mezquita, Inmaculada Ibañez de Cáceres, Angel Ayuso Sacido, Jose Maria Peña, Rosario Perona
  2012 ASCO Annual meeting. Poster

• New-onset hypothyroidism and macrocytosis as surrogate markers for the efficacy of sunitinib in the treatment of advanced renal cell carcinoma
  A. Pinto, V. Moreno García, E. Espinosa, A. Redondo, M. Gonzalez Barón.
  2010 Genitourinary Cancers Symposium. Poster.

• Use of a rectal cancer 13-gene signature to predict treatment response and patient outcome
  E. Casado, V. Moreno García, J. J. Sanchez, M. Blanco, J. Feliu, J. Maurel, C. Fernandez Martos, J. De Castro, M. Gonzalez Barón, P. Cejas
  2010 Gastrointestinal Cancer Symposium. Poster

• Accuracy of integrated PET-CT for mediastinal lymph node metastases in non-small cell lung cancer
  Moreno García V, De Castro Carpeño J, Feliu Batlle J, Belda C, Barriuso J, Martínez Marín V, Marín Ferrer MD, González Barón, M.
  Joint ECCO 15-34th ESMO Congress. Poster.

• Immunohistochemical analysis of tumor regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
  Moreno García V, Cejas P, Blanco M, Feliu J, Castro J, Belda C, Barriuso J, Sanchez JJ, Gonzalez Baron M.
  2009 ASCO Annual Meeting.

• Prognostic Value of Carcinoembryonic Antigen Level in Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy.
  Moreno García V, Cejas P, Blanco M, Feliu J, Castro J, Belda C, Barriuso J, Sanchez JJ, Gonzalez Baron M.
  2009 Gastrointestinal Cancer Symposium. San Francisco, California. USA.

• Is hepcidin involved in anemia of advanced non-small cell lung carcinoma (NSCLC) patients treated with platin-based chemotherapy? An exploratory study.
  J. De Castro, P. Cejas, C. Belda-Iniesta, N. Ramirez-Merino, J. Barriuso, E. Hernandez-Agudo, J. Feliu, V. Moreno-Garcia, V. Martinez-Marin, M. Gonzalez-Baron;
  2009 ASCO Annual Meeting. Abstract Book.

• Evaluation of the antitumour activity of interleukin 12 in an experimental murine model of colorectal cancer induced by dimethylhydrazine.
  Coca S, Enrech S, Moreno Garcia V. Pérez Piqueras J.
  11Th United European Gastroenterology Federation.

NACIONALES:

• Correlación clínico-molecular de la variante III del factor de crecimiento epidérmico (EGFRvIII) en gliomas de alto grado.
  Victor Moreno García, Juan Luis Arranz, Cristina Chamizo,Victoria Casado, Nerea Carvajal, Yann Izarzugaza, Lina Daoud,Miriam Dorta, Gloria Serrano, Federico Rojo, Jesús García-Foncillas
  2014. Simposio SEOM. Poster expuesto.

• Expresión de marcadores de hipoxia en el glioblastoma multiforme
  Víctor Moreno Garcia, Cristian Perna, Ana Castaño, Inés Gómez de la Riva, Alberto Isla, Juan Rey, Jaime Feliu, M. Mendiola.
  2013. XV Congreso nacional SEOM. Poster.

• Tratamiento de segunda línea con fotemustina en pacientes con glioblastoma multiforme.
  Víctor Moreno García, Patricia Cruz, Elsa Bernal, Nuria Rodríguez, Virginia Martínez, Ana Custodio, Javier de Castro y Jaime Feliu.
  2013. XV Congreso nacional SEOM. Poster.

• Nuevos Criterios Pronósticos para la seleccion de pacientes en ensayos Fase-I en cáncer: Resultados de un estudio multi-institucional de la European Drug Development Network (EDDN).
  Rafael Morales Barrer1, David Olmos, Gaetano Aurilio, Jordi Rodón, Victor Moreno García, Jesús Corral, Jaap Verweij, Jean-Charles Soria, Stan B Kaye, Josep Tabernero.
  XIV Congreso Nacional SEOM. Poster. 2011

• Immunohistochemical analysis of tumor regression grade for rectal cancer after neoadjuvant chemoradiotherapy (Análisis Inmunohistoquímico del Grado de Regresión Tumoral en Cáncer de Recto Tratado con Quimiorradioterapia Preoperatorio)
  Moreno Garcia V, Cejas P, Feliu J, Castro J, Belda C, Barriuso J, Larraur Ji, Sanchez JJ, González-Baron M, Casado E.
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). Oral Presentation. 2009

• Accuracy of integrated PET-CT for mediastinal lymph node metastases in non-small cell lung cancer. (Precisión del PET-TAC en la estadificación ganglionar del cáncer de pulmón no microítico).
  Moreno García V, De Castro Carpeño J, Feliu Batlle J, Belda C, Barriuso J, Martínez Marín V, Marín Ferrer MD, González Barón, M.
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). Poster . 2009

• Treatment with Docetaxel-Gemcitabina in soft tissue sarcomas, activity and toxicity. (Tratamiento con Docetaxel-Gemcitabina en sarcomas de partes blandas. Toxicidad y actividad).
  Martinez V, Redondo A, Zamora P, Espinosa E, Castelo B, Pinto A, Moreno García V, Aguayo C, Feliu J, González Barón M.
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). 2009

• Combined tratment for depresion in oncology patients improves quality of life. (El tratamiento combinado para la depresión en pacientes oncológicos mejora la calidad de vida).
  Castelo Fernández B, Torres G, Palao A, Redondo A, Pinto A, Zamora P, Espinosa E, Moreno García V, Rodriguez B, Gonzalez Barón M.
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). Poster. 2009

• Treatment of recurrent ovarian cancer with bevacizumab. (Tratamiento del cáncer de ovario recurrente con bevacizumab).
  Redondo Sánchez A, Zamora P, Espinosa E, Gómez C, Castelo B, Pinto A, Moreno García V, González R, Merino M, González Barón M.
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). Poster. 2009

• Validation of Rectal Prognostic Index in rectal cancer after neoadjuvant chemoradiotherapy. (Validación del índice pronóstico rectal (rectal prognostic index: RPI) en cáncer de recto tratado con quimiorradioterapia preoperatorio)
  Moreno García V,Cejas P, Feliu Batlle J, De Castro Carpeño J, Belda C, Barriuso C, Martínez Marín V, Larrauri J, Sanchez JJ, González Barón M, Casado E
  XII National Congress of the Spanish Society of Medical Oncology (SEOM). Poster. 2009

• Bevacizumab en combinación con quimioterapia en cáncer de ovario refractario. (Bevacizumab and chemotherapy in advanced ovarian cancer)
  Moreno García V, Zamora P, Espinosa E, Redondo A, González Baron M.
  XI National Congress of the Spanish Society of Medical Oncology (SEOM). 2007

• Cáncer gástrico en pacientes jóvenes, experiencia en un servicio de oncología. (Gastric cancer in young patients. Single institucional experience)
  E Luepke, M Sereno, A Pinto, C Raposo, V Moreno García, E Hernández, J Domingo, C Belda, J Barriuso y Manuel González-Barón
  XI National Congress of the Spanish Society of Medical Oncology (SEOM). 2007